I now have comprehensive information from Miller's Anesthesia and Katzung's Pharmacology. Let me compile the full guide.
π Thiopentone Sodium β Complete Guide
Source: Miller's Anesthesia 10th Ed. | Katzung's Basic & Clinical Pharmacology 16th Ed. | Goodman & Gilman's
π§ͺ Chemical Identity
| Property | Detail |
|---|
| Full name | Thiopental sodium (Thiopentone sodium in UK) |
| Drug class | Thiobarbiturate (ultrashort-acting barbiturate) |
| Chemical feature | Sulfur atom at C2 position of barbituric acid ring β makes it highly lipid-soluble with rapid onset |
| pKa | 7.6 β ~50% nonionized at physiologic pH 7.4, enabling rapid CNS penetration |
| pH of solution | 10β11 (highly alkaline β important for drug interactions) |
| Historical note | Introduced into clinical practice in 1934, marking the beginning of modern IV anesthesia |
Chemical Structure
The sulfur at position C2 (vs. oxygen in oxybarbiturates) gives thiopental its rapid onset and high lipid solubility.
βοΈ Mechanism of Action
Thiopentone acts via two main mechanisms:
1. GABA-A Receptor Potentiation (Primary)
- Binds to GABA-A receptor (a Clβ» ion channel)
- At low concentrations: Enhances GABA's effect β increases duration of Clβ» channel opening β hyperpolarization β sedation/hypnosis
- At higher concentrations: Acts as GABA mimetic itself β opens Clβ» channels even without GABA β produces full anesthesia
- Net result: Increased Clβ» conductance β hyperpolarized neuron β raised threshold for firing
2. Inhibition of Excitatory Transmission (Secondary)
- Blocks glutamate (NMDA-gated currents) in a concentration-dependent manner
- Decreases extracellular glutamate levels in the CNS
- Also reduces acetylcholine synaptic transmission
Key point: Unlike benzodiazepines (which only increase frequency of Clβ» channel opening), barbiturates also increase the duration of opening AND can directly activate channels at high doses.
π Pharmacokinetics
Distribution & Redistribution
| Phase | What Happens |
|---|
| Onset | Drug enters highly perfused brain within 30 seconds of IV injection |
| Termination of single dose | Due to redistribution β drug moves from brain β lean muscle tissue (NOT due to metabolism) |
| Recovery after single dose | Comparable to propofol β rapid awakening |
| Repeated doses / infusion | Drug saturates peripheral compartments β recovery markedly prolonged (depends on slow hepatic metabolism) |
Key Pharmacokinetic Values
| Parameter | Value |
|---|
| Onset | < 30 seconds IV |
| Duration (single dose) | 5β10 minutes |
| Elimination half-life | Long (hours) β due to redistribution |
| Protein binding | High (~85%) |
| Volume of distribution | Large β slightly bigger in women and in pregnancy |
Metabolism
- Hepatic β by 4 processes:
- Oxidation at C5 (most important) β polar metabolites excreted in urine
- N-dealkylation
- Desulfuration at C2 (removes the sulfur)
- Destruction of barbituric acid ring (minor)
- Metabolites are inactive, water-soluble β excreted in urine/bile
- NOT significantly altered by liver cirrhosis (unusually β liver clearance preserved)
- In large doses (300β600 mg/kg): switches from first-order β zero-order kinetics (Michaelis-Menten saturation)
π₯ Clinical Uses & Dosage
| Indication | Dose | Route |
|---|
| Induction of general anesthesia | 3β5 mg/kg IV | IV bolus |
| Refractory status epilepticus | Higher doses (titrated to isoelectric EEG) | IV infusion |
| Raised ICP / neuroprotection | Titrated to burst suppression on EEG | IV infusion |
| Rectal induction (children) | 20β30 mg/kg | Per rectum |
- Unconsciousness occurs in < 30 seconds
- Patients may notice a garlic or onion taste after injection
- β οΈ DO NOT mix with depolarizing or non-depolarizing muscle relaxants in the same syringe β precipitation of insoluble thiopentone acid occurs (very different pH)
π« Organ System Effects
CNS Effects
| Effect | Detail |
|---|
| Dose-dependent CNS depression | Sedation β hypnosis β anesthesia β coma |
| No analgesia | May actually reduce pain threshold (hyperalgesia at subhypnotic doses) |
| Cerebral vasoconstriction | β Cerebral blood flow (CBF) β Cerebral blood volume β ICP |
| β CMRO2 | Reduces cerebral metabolic oxygen consumption (dose-dependent, up to isoelectric EEG) |
| Neuroprotection | From focal ischemia (stroke, surgical retraction, aneurysm surgery) β not for global ischemia (e.g., cardiac arrest) |
| Anticonvulsant | Yes β suppresses EEG activity; used in refractory status epilepticus |
| Amnesia | Less pronounced than benzodiazepines |
| EEG | Progressively slows β burst suppression β isoelectric EEG at maximum dose |
Note: ICP decreases more than MAP after thiopental, preserving cerebral perfusion pressure (CPP = MAP β ICP). This is why it is useful in neurosurgery.
Cardiovascular Effects
- β Blood pressure β primarily from peripheral vasodilation
- Negative inotrope β direct depression of cardiac contractility
- Baroreceptor reflex less inhibited than with propofol β compensatory β heart rate limits hypotension
- β οΈ More dangerous in: hypovolemia, cardiac tamponade, cardiomyopathy, coronary artery disease β these patients cannot compensate for vasodilation
- Hypotension worsened by: large doses, rapid injection rate
Respiratory Effects
- Respiratory depressant β typical induction dose causes transient apnea
- β Tidal volume + β respiratory rate β β minute ventilation
- β Ventilatory response to hypercapnia and hypoxia
- Laryngeal and cough reflexes less suppressed than propofol β inferior choice for airway instrumentation without muscle relaxants
- Risk of laryngospasm or bronchospasm if airway stimulated during light anesthesia
β οΈ Adverse Effects & Complications
| Complication | Details |
|---|
| Transient apnea | After induction dose β have airway equipment ready |
| Hypotension | More severe in hypovolemic/cardiac patients |
| Laryngospasm / bronchospasm | If airway manipulated under light anesthesia |
| Intra-arterial injection | Causes excruciating pain + intense vasoconstriction β gangrene. Treat with stellate ganglion block + local lidocaine 0.5% (5β10 mL) to dilute drug |
| Extravasation | Tissue necrosis (highly alkaline solution) β inject local lidocaine |
| Histamine release | Occasional β bronchospasm, urticaria |
| Allergic reactions | Rare β 1 in 30,000 patients; life-threatening anaphylaxis possible |
| Hyperalgesia | At sub-hypnotic blood levels β lowers pain threshold |
| Hangover / prolonged sedation | After repeated doses or infusion due to accumulation |
π« Contraindications
| Contraindication | Reason |
|---|
| Acute intermittent porphyria | Barbiturates stimulate Ξ³-aminolevulinic acid synthetase β β porphyrin production β precipitates acute porphyric crisis |
| Severe hypovolemia / shock | Profound hypotension risk |
| Airway obstruction / difficult airway | Respiratory depression + β airway reflexes |
| Known hypersensitivity to barbiturates | Anaphylaxis risk |
| No IV access | Cannot use without reliable IV line |
π¬ StructureβActivity Relationship
| Position | Substitution | Effect |
|---|
| C2 β Sulfur (instead of oxygen) | Thiobarbiturate | β Lipid solubility β faster onset |
| C5 β Alkyl/aryl groups | Hypnotic & sedative effect | Longer side chains = more potent |
| C5 β Phenyl group | Anticonvulsant activity | e.g., phenobarbital |
| N1 β Methyl group | Even faster onset | e.g., methohexital (but causes excitatory side effects) |
π Thiopentone vs. Propofol (Key Comparison)
| Feature | Thiopentone | Propofol |
|---|
| Onset | < 30 sec | < 30 sec |
| Recovery (single dose) | Similar | Similar |
| Recovery (infusion) | Prolonged (accumulates) | Short (context-sensitive) |
| Blood pressure β | Moderate | More pronounced |
| Antiemetic | No | Yes |
| Neuroprotection | Yes | Minimal |
| Anticonvulsant | Yes | Limited |
| Pain on injection | No (IV) | Common |
| Porphyria | Contraindicated | Safe |
| Current role | Largely replaced by propofol | First-line IV induction |
π§ Memory Summary
THIOPENTONE = "The GABA GAP Closer"
G β GABA potentiation (prolongs Clβ» channel opening)
A β Anesthesia induction (3β5 mg/kg IV)
B β Brain protective (β ICP, β CMRO2)
A β Apnea + Apnoea risk
G β Garlic/onion taste on injection
A β Avoid in Porphyria (ABSOLUTE contraindication)
P β Precipitation with muscle relaxants (pH mismatch)
π Quick Reference Card
| Property | Value |
|---|
| Class | Thiobarbiturate |
| Mechanism | GABA-A potentiation + glutamate block |
| Dose (induction) | 3β5 mg/kg IV |
| Onset | < 30 seconds |
| Duration (single dose) | 5β10 minutes |
| Termination mechanism | Redistribution |
| Metabolism | Hepatic (oxidation) |
| Key CNS effect | β ICP, β CMRO2, anticonvulsant |
| Key CVS effect | β BP (vasodilation + neg. inotropy) |
| Key respiratory effect | Transient apnea |
| Absolute contraindication | Acute intermittent porphyria |
| Dangerous complication | Intra-arterial injection β gangrene |
| Key drug interaction | Precipitates with suxamethonium/muscle relaxants |
β Miller's Anesthesia, 10th Edition | Katzung's Basic & Clinical Pharmacology, 16th Edition | Goodman & Gilman's The Pharmacological Basis of Therapeutics